{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:40:08Z","timestamp":1776872408346,"version":"3.51.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin Co,. Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To clarify particularly how febrile neutropenia-related hospitalization (FNH) affects patients\u2019 daily lives, by analyzing real-world data on FNH among patients with early breast cancer (EBC) receiving perioperative chemotherapy in Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective nationwide large-scale database study was conducted using anonymized claims data from 2010 to 2020. The patients with EBC who had available surgical records were included. Men, those aged\u2009&lt;\u200918\u00a0years, and those who had not available chemotherapy records were excluded. FNH was defined as hospitalization during perioperative chemotherapy for EBC, with administration of intravenous antibacterial drugs and a diagnosis of FN, sepsis, infection, or fever.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The analysis population included 33,310 EBC patients with a mean age of 56.9\u00a0years, who received a total of 267,535 perioperative chemotherapy cycles. FNH occurred in 1,910 patients (5.73%) and 2144 chemotherapy cycles (0.80%). Median duration of FNH was 6.0\u00a0days. Fourth-generation cephalosporins were the most used intravenous antibacterial drugs (50.42%). Median duration of intravenous antibacterial drugs administration was 4.0\u00a0days. Therapeutic granulocyte-colony stimulating factor (G-CSF) was used in 1285 patients (67.28%). Median cost for FNH was estimated to be 189\u00a0thousand yen in 1,474 chemotherapy cycles with FNH, in which patients received intravenous antibacterial drugs administration for 3\u20138\u00a0days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This nationwide real-world data analysis revealed the incidence, duration, treatment patterns, and medical cost of FNH in patients with EBC receiving perioperative chemotherapy in Japan. These findings indicate that FNH imposes a considerable burden on patients\u2019 daily lives, including time and financial impacts, contributing to the implementation of appropriate shared decision-making for primary G-CSF prophylaxis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12282-025-01714-6","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:15:22Z","timestamp":1747631722000},"page":"857-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world evidence of febrile neutropenia-related hospitalization on patients with perioperative chemotherapy for early breast cancer in Japan"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8747-3641","authenticated-orcid":false,"given":"Tetsuhiro","family":"Yoshinami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8647-5098","authenticated-orcid":false,"given":"Nobuhiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Nukada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2093-3353","authenticated-orcid":false,"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"1714_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","volume":"13","author":"J Anampa","year":"2015","unstructured":"Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015;13:195. https:\/\/doi.org\/10.1186\/s12916-015-0439-8.","journal-title":"BMC Med"},{"key":"1714_CR2","doi-asserted-by":"publisher","first-page":"107327482312091","DOI":"10.1177\/10732748231209193","volume":"30","author":"W Hu","year":"2023","unstructured":"Hu W, Xu D, Li N. Research status of systemic adjuvant therapy for early breast cancer. Cancer Control. 2023;30:10732748231209192. https:\/\/doi.org\/10.1177\/10732748231209193.","journal-title":"Cancer Control"},{"key":"1714_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12282-023-01505-x","volume":"30","author":"M Terada","year":"2023","unstructured":"Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, et al. The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2022 edition. Breast Cancer. 2023;30:872\u201384. https:\/\/doi.org\/10.1007\/s12282-023-01505-x.","journal-title":"Breast Cancer"},{"key":"1714_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol"},{"key":"1714_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021;39:1485\u2013505. https:\/\/doi.org\/10.1200\/JCO.20.03399.","journal-title":"J Clin Oncol"},{"key":"1714_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/oxfordjournals.jncimonographs.a003451","volume":"30","author":"AH Partridge","year":"2001","unstructured":"Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001;30:135\u201342. https:\/\/doi.org\/10.1093\/oxfordjournals.jncimonographs.a003451.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"1714_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228\u201337. https:\/\/doi.org\/10.1002\/cncr.11882.","journal-title":"Cancer"},{"key":"1714_CR8","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.3390\/curroncol30030244","volume":"30","author":"F Khan","year":"2023","unstructured":"Khan F, Black M, Charlton A, Younus J. Primary prophylaxis Lapelga\u00ae in early breast cancer: a real-world experience. Curr Oncol. 2023;30:3217\u201322. https:\/\/doi.org\/10.3390\/curroncol30030244.","journal-title":"Curr Oncol"},{"key":"1714_CR9","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258\u201366. https:\/\/doi.org\/10.1002\/cncr.21847.","journal-title":"Cancer"},{"key":"1714_CR10","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00520-017-3692-x","volume":"25","author":"AA Kawatkar","year":"2017","unstructured":"Kawatkar AA, Farias AJ, Chao C, Chen W, Barron R, Vogl FD, et al. Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer. 2017;25:2787\u201395. https:\/\/doi.org\/10.1007\/s00520-017-3692-x.","journal-title":"Support Care Cancer"},{"key":"1714_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00520-014-2553-0","volume":"23","author":"R Pathak","year":"2015","unstructured":"Pathak R, Giri S, Aryal MR, Karmacharya P, Bhatt VR, Martin MG. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. Support Care Cancer. 2015;23:615\u20137. https:\/\/doi.org\/10.1007\/s00520-014-2553-0.","journal-title":"Support Care Cancer"},{"key":"1714_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist. 2022;27:625\u201336. https:\/\/doi.org\/10.1093\/oncolo\/oyac074.","journal-title":"Oncologist"},{"key":"1714_CR13","unstructured":"Japan Society of Clinical Oncology. Clinical Practice Guidelines for the Use of G-CSF 2022 (ver. 2). (in Japanese) http:\/\/www.jsco-cpg.jp\/g-csf\/. Accessed 22 Apr 2025."},{"key":"1714_CR14","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199\u2013212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488.","journal-title":"J Clin Oncol"},{"key":"1714_CR15","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Version 3.2024. Hematopoietic Growth Factors. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493. Accessed 22 Apr 2025."},{"key":"1714_CR16","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1200\/JCO.2016.67.2899","volume":"34","author":"A Agiro","year":"2016","unstructured":"Agiro A, Ma Q, Acheson AK, Wu S, Patt DA, Barron JJ, et al. Risk of neutropenia-related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer. J Clin Oncol. 2016;34:3872\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.67.2899.","journal-title":"J Clin Oncol"},{"key":"1714_CR17","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s10147-024-02570-8","volume":"29","author":"K Nozawa","year":"2024","unstructured":"Nozawa K, Ozaki Y, Yoshinami T, Yokoe T, Nishio H, Tsuchihashi K, et al. Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022. Int J Clin Oncol. 2024;29:1074\u201380. https:\/\/doi.org\/10.1007\/s10147-024-02570-8.","journal-title":"Int J Clin Oncol"},{"key":"1714_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JOP.2013.001369","volume":"10","author":"PA Ganz","year":"2014","unstructured":"Ganz PA. Institute of Medicine report on delivery of high-quality cancer care. J Oncol Pract. 2014;10:193\u20135. https:\/\/doi.org\/10.1200\/JOP.2013.001369.","journal-title":"J Oncol Pract"},{"key":"1714_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1634\/theoncologist.2018-0711","volume":"24","author":"GB Rocque","year":"2019","unstructured":"Rocque GB, Rasool A, Williams BR, Wallace AS, Niranjan SJ, Halilova KI, et al. What is important when making treatment decisions in metastatic breast cancer? A qualitative analysis of decision-making in patients and oncologists. Oncologist. 2019;24:1313\u201321. https:\/\/doi.org\/10.1634\/theoncologist.2018-0711.","journal-title":"Oncologist"},{"key":"1714_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s12282-020-01139-3","volume":"27","author":"N Hayashi","year":"2020","unstructured":"Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K. Annual report of the Japanese breast cancer registry for 2017. Breast Cancer. 2020;27:803\u20139. https:\/\/doi.org\/10.1007\/s12282-020-01139-3.","journal-title":"Breast Cancer"},{"key":"1714_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-023-07015-w","volume":"201","author":"N Shibata","year":"2023","unstructured":"Shibata N, Yoshinami T, Tamaki K, Nukada T, Ohno S. Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer. Breast Cancer Res Treat. 2023;201:265\u201373. https:\/\/doi.org\/10.1007\/s10549-023-07015-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1714_CR22","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00520-019-05080-w","volume":"28","author":"S Li","year":"2020","unstructured":"Li S, Liu J, Guo H, Gawade PL, Kim C, Bensink ME, et al. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995\u20132015. Support Care Cancer. 2020;28:2637\u201349. https:\/\/doi.org\/10.1007\/s00520-019-05080-w.","journal-title":"Support Care Cancer"},{"key":"1714_CR23","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","volume":"40","author":"A Gupta","year":"2022","unstructured":"Gupta A, Eisenhauer EA, Booth CM. The time toxicity of cancer treatment. J Clin Oncol. 2022;40:1611\u20135. https:\/\/doi.org\/10.1200\/JCO.21.02810.","journal-title":"J Clin Oncol"},{"key":"1714_CR24","unstructured":"Japanese Society of Medical Oncology. Practical Guideline of Febrile Neutropenia (FN) (3rd edition). 2024 (in Japanese)."},{"key":"1714_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3918\/jsicm.29_107","volume":"29","author":"E Hashiba","year":"2022","unstructured":"Hashiba E, Takekawa D, Endo H, Hirota K. Analysis of prolonged length of stay in intensive care units in Japan using the Japanese intensive care patient database. J Jpn Soc Intensive Care Med. 2022;29:107\u201316. https:\/\/doi.org\/10.3918\/jsicm.29_107","journal-title":"J Jpn Soc Intensive Care Med."},{"key":"1714_CR26","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1007\/s00520-021-06277-8","volume":"29","author":"N Akiyama","year":"2021","unstructured":"Akiyama N, Okamura T, Yoshida M, Kimura SI, Yano S, Yoshida I, et al. A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology-oncology physicians and surgeons. Support Care Cancer. 2021;29:6831\u20139. https:\/\/doi.org\/10.1007\/s00520-021-06277-8.","journal-title":"Support Care Cancer"},{"key":"1714_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404. https:\/\/doi.org\/10.1186\/1471-2407-11-404.","journal-title":"BMC Cancer"},{"key":"1714_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1186\/s12885-019-6010-9","volume":"19","author":"D Weycker","year":"2019","unstructured":"Weycker D, Doroff R, Hanau A, Bower C, Belani R, Chandler D, et al. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. BMC Cancer. 2019;19:792. https:\/\/doi.org\/10.1186\/s12885-019-6010-9.","journal-title":"BMC Cancer"},{"key":"1714_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-021-06387-1","volume":"190","author":"H Van Belle","year":"2021","unstructured":"Van Belle H, Hurvitz SA, Gilbar PJ, Wildiers H. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. Breast Cancer Res Treat. 2021;190:357\u201372. https:\/\/doi.org\/10.1007\/s10549-021-06387-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1714_CR30","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1177\/10781552211030974","volume":"28","author":"J Zekri","year":"2022","unstructured":"Zekri J, Nawaz A, Rasool H, Ahmad I, Abdel Rahman H, Dada R, et al. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer. J Oncol Pharm Pract. 2022;28:1681\u20136. https:\/\/doi.org\/10.1177\/10781552211030974.","journal-title":"J Oncol Pharm Pract"},{"key":"1714_CR31","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1007\/s00520-019-05111-6","volume":"28","author":"CF Lee","year":"2020","unstructured":"Lee CF, Zhou K, Young WM, Wong CS, Ng TY, Lee SF, et al. Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: a retrospective cohort study on duration of prophylactic GCSF administration. Support Care Cancer. 2020;28:3801\u201312. https:\/\/doi.org\/10.1007\/s00520-019-05111-6.","journal-title":"Support Care Cancer"},{"key":"1714_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00520-016-3421-x","volume":"25","author":"D Weycker","year":"2017","unstructured":"Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer. 2017;25:439\u201347. https:\/\/doi.org\/10.1007\/s00520-016-3421-x.","journal-title":"Support Care Cancer"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01714-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01714-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01714-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:44:55Z","timestamp":1750164295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01714-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01714-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T Yoshinami has received speaker honoraria from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Eisai Co., Ltd., AstraZeneca K.K., and Pfizer Japan Inc. N Shibata received consulting fees for Advisory Board from Kyowa Kirin Co., Ltd., and Daiichi Sankyo Co., Ltd., and honoraria from Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Merck Biopharma Co., Ltd., and Bristol Myers Squibb K.K., and research funding from Daiichi Sankyo Co., Ltd., MSD K.K., and AstraZeneca K.K. K Tamaki has no competing interest to declare. K Ishimaru, S Ito and T Nukada are employees of Kyowa Kirin Co., Ltd. S Ohno has received speaker honoraria from Kyowa Kirin Co., Ltd, Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K., and Nippon Kayaku Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Research Institute of Healthcare Data Science (RI2021015). According to the \u201cEthical Guidelines for Medical and Health Research Involving Human Subjects\u201d, a study using secondary data stored in an anonymized structured format, such as this study, is outside the scope of the guidelines. Informed consent was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}